Rodman David Malcom Buys Shares of Mineralys Therapeutics, Inc. $MLYS
Key Points
- Rodman David Malcom bought 6,349 shares of Mineralys Therapeutics, Inc. ($MLYS) worth $6,857.
- $MLYS last traded around $23.62.
Rodman David Malcom, Chief Medical Officer at Mineralys Therapeutics, Inc. ($MLYS), bought 6,349 shares at an average price of $1.08, for a total transaction of $6,857. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Mineralys Therapeutics, Inc. ($MLYS) Stock
Mineralys Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.